Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
Psychopharmacology January 2, 2019 Thomas Anderson, Rotem Petranker, Daniel Rosenbaum et al. 171 citations
No Summary
Lê-Anh Dinh-Williams
The Scarborough Hospital
4 papers in the library · 387 citations · publishing 2018-2020
Papers
Psychedelic microdosing benefits and challenges: an empirical codebook
Harm Reduction Journal July 9, 2019 Thomas Anderson, Rotem Petranker, Adam Christopher et al. 130 citations
A mixed-methods study of an active microdosing community categorizes the experiences participants report, identifying high-potential avenues for future scientific research. The resulting taxonomy distills intervention targets from participant reports to help allocate research funding efficiently. Microdosing research complements full-dose psychedelic studies as clinical treatments and neuropharmacological mechanisms are developed. The framework aims to guide researchers and clinicians as experimental microdosing research begins in earnest.
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities
Journal of Psychopharmacology February 28, 2020 Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson et al. 75 citations
People who microdose psychedelics—taking small, non-hallucinogenic amounts of LSD or psilocybin—are less likely to report a history of substance use disorders or anxiety disorders than non-microdosers, but more likely to report recent recreational substance use. Among 909 participants recruited from Reddit, most microdosers used LSD (59.3%) or psilocybin (25.9%) on a one-day-on, two-days-off schedule. The findings suggest that microdosers differ from non-microdosers in psychiatric and substance-use profiles, and well-designed randomized controlled trials are needed to evaluate safety and potential benefits in clinical populations.
Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers
November 1, 2018 Thomas Anderson, Rotem Petranker, Daniel M. Rosenbaum et al. 11 citations preprint
People who regularly consume small amounts of psychedelics like LSD or psilocybin—a practice called microdosing—report lower levels of dysfunctional attitudes and negative emotionality, and higher levels of wisdom, open-mindedness, and creativity compared to those who do not microdose. This pre-registered study, the first to investigate microdosing and mental health, recruited participants from online forums. Although promising, the findings are preliminary and warrant controlled experimental research to test safety and clinical efficacy. Microdosing may offer clinical benefits without the hallucinogenic effects of full-dose psychedelic therapy.